Epistemic AI is a technology company.
Epistemic AI has raised $6.0M across 1 funding round.
Epistemic AI has raised $6.0M in total across 1 funding round.
Epistemic AI has raised $6.0M in total across 1 funding round.
Epistemic AI's investors include 2048 Ventures, Alpha Prime Fund, Anthemis Group, C2Ventures, Cowboy Ventures, Evening Fund, Oak HC/FT, Dan Raveh, Jeff Seltzer.
Epistemic AI is a technology company building a Knowledge Discovery platform powered by AI to accelerate biomedical research and drug discovery. It integrates hundreds of biomedical knowledge sources via proprietary technologies like Knowledge Mapping and EpistemicGPT—a large language model combined with a knowledge graph of over 6 billion nodes and 20 billion connections—to uncover hidden relationships between genes, diseases, pathways, drugs, companies, and people.[1][2][4][6] The platform serves pharmaceutical companies, researchers, non-profits, government agencies, and life sciences institutions, solving the problem of siloed information and slow knowledge extraction from vast datasets to enable faster hypotheses generation, competitive intelligence, biomarker discovery, and drug development decisions.[1][2][4][5][6] Recent growth includes a strategic investment from ClearView Healthcare Partners in January 2025, enabling platform integration into consulting services and partnerships to decentralize AI in life sciences.[4][6]
Epistemic AI was co-founded by Stefano Pacifico (CEO) and David Heeger, with a team blending software developers, AI scientists, biomedical experts, and business professionals dedicated to accelerating discoveries for better patient outcomes.[1] The idea emerged from the need to link science and strategy through AI, starting with applications in pharmaceuticals like merging public and proprietary sources for drug-safety monitoring and explainable insights.[1][5] Early traction built around its core Knowledge Mapping technology, evolving into a full platform with tools like KOL Maps, PhenoMaps, and EpistemicGPT; pivotal momentum came from investors including Ray Schiavone, Zorba Lieberman, Noel Hall, Alessandro Piol, and David McClain, plus the 2025 ClearView investment signaling validation in biopharma.[1][4][6] Note: A separate EU-funded Epistemic AI project (epistemic-ai.eu) focuses on theoretical "epistemic uncertainty" in AI but appears distinct from this commercial platform.[3][7]
Epistemic AI rides the AI-for-drug-discovery wave, where generative AI and knowledge graphs address life sciences' data explosion amid rising R&D costs and regulatory pressures. Timing aligns with post-2023 LLM advancements, enabling scalable biomedical analysis when traditional methods fail in complex, uncertain environments.[2][4][6] Market forces like biopharma's push for faster trials, personalized medicine, and decentralized AI favor it, as platforms like this cut discovery timelines and democratize access to siloed data.[1][4][6] It influences the ecosystem by partnering with consultancies like ClearView to embed AI in workflows, potentially standardizing "research intelligence" and accelerating outcomes from basic research to commercialization.[4][5][6]
Epistemic AI is poised to expand via deepened pharma integrations and platform iterations shaped by ClearView's expertise, targeting broader adoption in drug safety, market entry, and biomarker hunting.[4][6] Trends like multimodal AI, regulatory AI validation, and epistemic uncertainty modeling (echoing related research) will propel it, evolving from niche tool to ecosystem backbone.[3][7] Its influence may grow by powering decentralized life sciences AI, directly tying back to its mission of faster discoveries for superior patient outcomes.[1]
Epistemic AI has raised $6.0M across 1 funding round. Most recently, it raised $6.0M Seed in April 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2021 | $6.0M Seed | 2048 Ventures, Alpha Prime Fund, Anthemis Group, C2Ventures, Cowboy Ventures, Evening Fund, Oak HC/FT, Dan Raveh, Jeff Seltzer |